Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Down 10.9% in August

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) saw a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 2,040,000 shares, a decline of 10.9% from the July 31st total of 2,290,000 shares. Approximately 3.4% of the shares of the company are sold short. Based on an average trading volume of 734,200 shares, the days-to-cover ratio is currently 2.8 days.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $115.98 on Monday. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $146.70. The stock’s 50-day moving average is $109.54 and its 200 day moving average is $112.73. The company has a market cap of $7.31 billion, a P/E ratio of 23.91, a PEG ratio of 1.45 and a beta of 0.58. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on JAZZ shares. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $173.07.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in JAZZ. Kovack Advisors Inc. raised its stake in Jazz Pharmaceuticals by 88.8% in the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after buying an additional 26,628 shares during the last quarter. Polaris Capital Management LLC raised its stake in Jazz Pharmaceuticals by 2.2% in the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after buying an additional 27,100 shares during the last quarter. John G Ullman & Associates Inc. purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at about $3,631,000. Swedbank AB purchased a new stake in Jazz Pharmaceuticals in the second quarter valued at about $106,936,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $380,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.